Monitoring the action of clodronate with type I collagen metabolites in multiple myeloma
- 1 June 1996
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 32 (7) , 1166-1170
- https://doi.org/10.1016/0959-8049(95)00653-2
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Subgroup and cost‐benefit analysis of the Finnish multicentre trial of clodronate in multiple myelomaBritish Journal of Haematology, 1994
- Bisphosphonates act on rat bone resorption through the mediation of osteoblasts.Journal of Clinical Investigation, 1993
- Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradationClinical Chemistry, 1993
- Clodronate for multiple myelomaThe Lancet, 1993
- Biochemical Markers of Bone MetabolismAnnals of Medicine, 1993
- Randomised, placebo-controlled multicentre trial of clodronate in multiple myelomaThe Lancet, 1992
- Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myelomaBritish Journal of Cancer, 1992
- Relationship of cell growth to the regulation of tissue‐specific gene expression during osteoblast differentiationThe FASEB Journal, 1990
- Abnormal serum bone gla protein levels in multiple myeloma: Crucial role of bone formation and prognostic implicationsCancer, 1990
- A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survivalCancer, 1975